1例滤泡性非霍奇金淋巴瘤持续新冠病毒阳性伴耶氏肺孢子菌肺炎的药物治疗调整与药学监护  

Adjustment of drug therapy and pharmaceutical care for a case of follicular non-Hodgkin lymphoma with persistent coronavirus positivity accompanied by Pneumocystis jirovecii pneumonia

作　　者：罗芬 张捷青[1] 叶晓芬 李晓宇 毕晶 LUO Feng;ZHANG Jieqing;YE Xiaofen;LI Xiaoyu;BI Jing(Department of Pharmacy,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Pharmacy,the Second Xiangya Hospital,Central South University,Changsha 410011,China;Respiratory Department,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院药剂科,上海200032 [2]中南大学湘雅二医院药学部,长沙410011 [3]复旦大学附属中山医院呼吸科,上海200032

出　　处：《上海医药》2024年第1期69-74,共6页Shanghai Medical & Pharmaceutical Journal

基　　金：湖南省自然科学基金资助项目(2020JJ5821)。

摘　　要：1例滤泡性非霍奇金淋巴瘤感染新冠病毒后持续阳性及并发急性呼吸窘迫综合征,多疗程抗病毒治疗后仍未转阴,同时合并三系降低,且继发了耶氏肺孢子菌肺炎、细菌感染、巨细胞病毒感染等,针对该免疫抑制宿主长病程的不同阶段,不同治疗矛盾,综合患者当时情况及药物特点及时进行了药物调整和药学监护,患者整体情况逐渐好转。本例反映了在复杂的病情变化中,药物治疗要抓住实时的主要矛盾,动态地调整治疗方案。A case of follicular non-Hodgkin lymphoma remained persistently positive for the coronavirus and developed acute respiratory distress syndrome(ARDS)after infection and his viral status did not revert to negative despite multiple courses of antiviral therapy,and meanwhile he experienced decrease in all three blood cell lines and developed secondary complications including Pneumocystis jirovecii pneumonia,bacterial infections and cytomegalovirus infection.Addressing the different stages of prolonged immunosuppression in the host,conflicting treatment strategies were identified.Considering the patient’s evolving condition,medication characteristics,timely adjustments to drug therapy and pharmaceutical monitoring were implemented.The patient’s overall condition was gradually improved.This case highlights the importance of capturing real-time primary contradictions in complex and evolving medical conditions,dynamically adjusting treatment plans.

关 键 词：滤泡性非霍奇金淋巴瘤 新型冠状病毒感染 耶氏肺孢子菌肺炎 药物治疗调整 药物监护 

分 类 号：R969.3[医药卫生—药理学]